Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis Cost of Revenue: $3,608M in Q3 2026, up 1.9% from a year earlier.
Latest, Q3 2026
3,608
Period ended Sep 30, 2026
Change on a year earlier
+1.9%
3,539 in Q3 2025
History
37 quarters
Since Q2 2017
Sources
32
Documents cited below
Where the Q3 2026 figure comes from
“|| Cost of goods sold | – 3 608 | – 3 539”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Postgres DB + Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis Cost of Revenue ($M), quarterly Q2 2017–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/db-is-cogs
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.